Back to Search Start Over

Stereotactic radiosurgery for treatment of radiation-induced meningiomas: a multiinstitutional study

Authors :
Jaromir Hanuska
Love Buch
Jennifer L. Peterson
Jason P. Sheehan
Adomas Bunevicius
Akiyoshi Ogino
Anne Marie Langlois
Ronald E Warnick
Hideyuki Kano
James McInerney
Gabriel Zada
Anissa Saylany
L. Dade Lunsford
Catherine Caldwell
Huai-Che Yang
Mohand Suleiman
Roberto Martínez Álvarez
Cheng-Chia Lee
Christine Mau
Daniel M. Trifiletti
Brad E. Zacharia
Samir Patel
Leonard Tuanquin
David Mathieu
Ben A. Strickland
John Y K Lee
Eric L. Chang
Nuria Martinez Moreno
Roman Liscak
Source :
Journal of Neurosurgery. 135:862-870
Publication Year :
2021
Publisher :
Journal of Neurosurgery Publishing Group (JNSPG), 2021.

Abstract

OBJECTIVE Radiation-induced meningiomas (RIMs) are associated with aggressive clinical behavior. Stereotactic radiosurgery (SRS) is sometimes considered for selected RIMs. The authors investigated the effectiveness and safety of SRS for the management of RIMs. METHODS From 12 institutions participating in the International Radiosurgery Research Foundation, the authors pooled patients who had prior cranial irradiation and were subsequently clinically diagnosed with WHO grade I meningiomas that were managed with SRS. RESULTS Fifty-two patients underwent 60 SRS procedures for histologically confirmed or radiologically suspected WHO grade I RIMs. The median ages at initial cranial radiation therapy and SRS for RIM were 5.5 years and 39 years, respectively. The most common reasons for cranial radiation therapy were leukemia (21%) and medulloblastoma (17%). There were 39 multiple RIMs (35%), the mean target volume was 8.61 ± 7.80 cm3, and the median prescription dose was 14 Gy. The median imaging follow-up duration was 48 months (range 4–195 months). RIM progressed in 9 patients (17%) at a median duration of 30 months (range 3–45 months) after SRS. Progression-free survival at 5 years post-SRS was 83%. Treatment volume ≥ 5 cm3 predicted progression (HR 8.226, 95% CI 1.028–65.857, p = 0.047). Seven patients (14%) developed new neurological symptoms or experienced SRS-related complications or T2 signal change from 1 to 72 months after SRS. CONCLUSIONS SRS is associated with durable local control of RIMs in the majority of patients and has an acceptable safety profile. SRS can be considered for patients and tumors that are deemed suboptimal, poor surgical candidates, and those whose tumor again progresses after removal.

Details

ISSN :
19330693 and 00223085
Volume :
135
Database :
OpenAIRE
Journal :
Journal of Neurosurgery
Accession number :
edsair.doi.dedup.....973882c2301252e17f2ce9012f4b6fcc
Full Text :
https://doi.org/10.3171/2020.7.jns202064